Search

Your search keyword '"Tracy, Irene"' showing total 8 results
Start Over Author "Tracy, Irene"
8 results on '"Tracy, Irene"'

1. Mapping of European activities on the integration of sex and gender factors in neurology and neuroscience.

Author

Hentzen, Nina B., Ferretti, Maria Teresa, Santuccione Chadha, Antonella, Jaarsma, Joke, De Visser, Marianne, Moro, Elena, Aamodt, Anne Hege, Arabia, Gennarina, Aybeck, Selma, Carvalho, Vanessa, Goudier, Riadh, Grisold, Wolfgang, Lebedeva, Elena R., Matczack, Magda, Magyari, Melinda, Molnar, Maria Judit, Rakusa, Martin, Pajediene, Evelina, Tracy, Irene, and Vonck, Kristl

Subjects
GENDER, EUROPEAN integration, NEUROSCIENCES, BIBLIOGRAPHIC databases, NEUROLOGY, QUANTITATIVE research
Abstract

Background and purpose: Neurological disorders pose a profound unmet medical need for which new solutions are urgently needed. The consideration of both biological (sex) and socio‐cultural (gender) differences between men and women is necessary to identify more efficacious, safer and tailored treatments. Approaches for putting sex and gender medicine into practice have gathered momentum across Europe, but it is currently unclear to what extent they have been implemented in the field of neurology and neuroscience. Methods: We mapped current activities in research, funding and education aimed at integrating sex and gender consideration in neuroscience and neurology in Europe. We examined and analyzed data gathered from literature searches, policy documents and reports by the European Commission and national funding agencies, web‐based searches, Web of Science, and searches of project databases of funding agencies. An informative/non‐systematic search was performed for sections on policies and funding, education, and basic research, while a systematic literature and database review was conducted for quantitative analysis of research output and funded projects in terms of sex and gender analysis. Results: Our mapping shows that there is a growing interest in and attention given to sex and gender considerations in neurological fields, both from funding agencies and researchers. However, most activities, especially for education, are limited to the individual motivation of researchers and are not organically built within curricula and strategic research priorities. Conclusion: We recommend actions that might help increase the consideration of sex and gender specifically in the field of neuroscience and neurology. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

2. De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study

Author

Hasserjian, Robert Paul, Campigotto, Federico, Klepeis, Veronica, Fu, Bin, Wang, Sa A., Bueso-Ramos, Carlos, Cascio, Michael Joseph, Rogers, Heesun Joyce, Hsi, Eric Darryl, Soderquist, Craig, Bagg, Adam, Yan, Jiong, Ochs, Rachel, Orazi, Attilio, Moore, Frank, Mahmoud, Amer, George, Tracy Irene, Foucar, Kathryn, Odem, Jamie, Booth, Cassie, Morice, William, DeAngelo, Daniel J., Steensma, David, Stone, Richard Maury, Neuberg, Donna, and Arber, Daniel Alan

Published
2014
Full Text
View/download PDF

4. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study

Author

Robert Paul, Hasserjian, Federico, Campigotto, Veronica, Klepeis, Bin, Fu, Sa A, Wang, Carlos, Bueso-Ramos, Michael Joseph, Cascio, Heesun Joyce, Rogers, Eric Darryl, Hsi, Craig, Soderquist, Adam, Bagg, Jiong, Yan, Rachel, Ochs, Attilio, Orazi, Frank, Moore, Amer, Mahmoud, Tracy Irene, George, Kathryn, Foucar, Jamie, Odem, Cassie, Booth, William, Morice, Daniel J, DeAngelo, David, Steensma, Richard Maury, Stone, Donna, Neuberg, and Daniel Alan, Arber

Subjects
Male, Karyotype, Cell Count, Kaplan-Meier Estimate, Bone Marrow, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Retrospective Studies, Aged, 80 and over, Chromosome Aberrations, Anemia, Refractory, with Excess of Blasts, Remission Induction, Age Factors, Hematopoietic Stem Cell Transplantation, Nuclear Proteins, DNA Methylation, Middle Aged, Prognosis, Neoplasm Proteins, Leukemia, Myeloid, Acute, Treatment Outcome, fms-Like Tyrosine Kinase 3, Mutation, Neoplastic Stem Cells, Female, Nucleophosmin
Abstract

It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10-19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4-year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P 0.0001), and stem cell transplant (P 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML.

Published
2014

5. De novoacute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study

Author

Hasserjian, Robert Paul, primary, Campigotto, Federico, additional, Klepeis, Veronica, additional, Fu, Bin, additional, Wang, Sa A., additional, Bueso-Ramos, Carlos, additional, Cascio, Michael Joseph, additional, Rogers, Heesun Joyce, additional, Hsi, Eric Darryl, additional, Soderquist, Craig, additional, Bagg, Adam, additional, Yan, Jiong, additional, Ochs, Rachel, additional, Orazi, Attilio, additional, Moore, Frank, additional, Mahmoud, Amer, additional, George, Tracy Irene, additional, Foucar, Kathryn, additional, Odem, Jamie, additional, Booth, Cassie, additional, Morice, William, additional, DeAngelo, Daniel J., additional, Steensma, David, additional, Stone, Richard Maury, additional, Neuberg, Donna, additional, and Arber, Daniel Alan, additional

Published
2014
Full Text
View/download PDF

6. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment

Author

Alarcon, Graciela S., Tracy, Irene C., and Blackburn, Warren D., Jr.

Subjects
Methotrexate -- Health aspects, Rheumatoid arthritis -- Drug therapy, Health
Abstract

Rheumatoid arthritis (RA), a chronic or long-term disease affecting the entire body, is characterized by inflammation of the joints and related structures, which results in crippling deformities. The cause of RA is not known, but the condition may be related to changes in the body's natural defense mechanisms, the immune system. The disease usually occurs in middle age, and is treated by bedrest, physiotherapy and exercise, and various drugs, including the antifolate agent methotrexate (MTX). The clinical and demographic features that affect the probability of patients continuing MTX treatment were examined in 152 RA patients treated with MTX between 1981 and 1986. The overall probability of continuing MTX was about 71 percent in the first year, 56 percent at three years, 50 percent at five years, and 49 percent at six years. Patients who started MTX treatment later in the study, American blacks, younger patients, those with less severe disease, and those experiencing less frequent and less severe toxic effects were more likely to continue MTX treatment. The time when MTX treatment was started and the incidence of toxic effects influenced the probability of continuing MTX therapy the most. Thus, the toxic effects of MTX appear to be the main reason for discontinuing MTX treatment. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results